(a) To characterize the frequency of objective cognitive deficits and self-perceived cognitive difficulties and (b) to explore demographic and clinical predictors of cognitive dysfunction and cognitive complaints. One hundred and ten adults diagnosed with COVID-19 between March and November 2020, aged ≤ 74 years underwent a brief neuropsychological evaluation 12 months after infection, which included: Brief Visuospatial Memory Test-Revised, California Verbal Learning Test, and Symbol Digit Modalities Test. T scores < 38 were considered abnormal performance; cognitive dysfunction was defined as ≥ 2 abnormal tests. Participants also completed Broadbent's Cognitive Failure Questionnaires (CFQ), Hospital Anxiety and Depression Scale, Modified Fatigue Impact Scale, and Short-Form Health Survey. CFQ ≥ 43 was considered indicative of cognitive complaints. Twenty participants (18.2%) had cognitive dysfunction and 36 (33.3%) had cognitive complaints. Cognitive dysfunction was related to lower education, preinfection history of headache/migraine, and acute COVID-19 symptoms of headache and sleep disturbance. Cognitive complaints were more likely to occur in women, those with fewer years of education, and acute COVID-19 symptoms of headache and sleep disturbance. Cognitive complaints were also significantly related to symptoms of anxiety, depression, and fatigue. Sex and psychopathology were not significant predictors of cognitive dysfunction. Modest associations were found between CFQ total score and cognitive test performance. A subset of individuals develops cognitive difficulties in the context of post-COVID syndrome. Results may support the protective effect of education, a known proxy of cognitive reserve. COVID-19 infection symptoms of headache and sleep disturbance appear to be risk factors for long-term cognitive difficulties. (PsycInfo Database Record (c) 2023 APA, all rights reserved).
Background: Headache is a symptom of the long‐COVID syndrome. The incidence and characteristics of de novo post‐COVID headaches remain unclear. Our aim was to characterize new‐onset headaches in a population‐based prospective cohort of COVID‐19 patients from the first pandemic wave.Methods: This study followed a prospective cohort of 732 COVID‐19 patients consecutively diagnosed between March and June 2020. Neurological follow‐up was performed face‐to‐face or by phone at 3, 12, and 24 months. A structured clinical questionnaire was used to characterize headaches before infection and 24 months postinfection.Results: Overall, 448 patients completed the 24‐month follow‐up, with a mean age of 51.6 years at SARS‐CoV‐2 infection; 272 (60.7%) were women. A prior history of headaches was reported by 115 (25.7%). Patients with either pre‐existing or de novo persistent headaches were younger, more often women, and exhibited hyposmia, hypogeusia, and headache during the acute phase of infection. De novo persistent headaches occurred in 54 of 333 (16.2%) headache‐naïve patients. Of these, 35 (64.8%) fulfilled migraine‐like headache (MLH) criteria (mean age of 49.1 years at 24‐month follow‐up), with a cumulative incidence of 42/1000/year.Conclusions: De novo persistent headaches are common 2 years after COVID‐19, with MLH being the most frequent type. MLH incidence after COVID‐19 is elevated and de novo “migraineurs‐like” tend to be older compared to the general population. This is an important finding with potential implications for healthcare and quality of life, considering the high number of COVID‐19 cases and the global burden of migraine.
Cluster headache (CH) has well-defined diagnostic criteria, but its diagnostic delay (DD) remains substantial, averaging 3.6 to 9 years, leading to inappropriate treatments and significant psychosocial and socioeconomic burdens. To identify demographic and clinical factors associated with DD in CH to promote earlier diagnosis. A multicenter cross-sectional study recruited 64 patients with episodic or chronic CH from 6 Portuguese neurology centers. Participants completed an online questionnaire covering demographics, clinical features, prior consultations, diagnoses, and treatments. Diagnostic delay was defined as the time from symptom onset to formal diagnosis. Correlation tests and multiple linear regression were performed to identify predictors of DD. The mean DD was of 6.4 ± 8.3 (range: 0–39) years, with 46.9% experiencing delays > 4 years. No sex differences were observed. Younger age at onset (ρ = –0.45; p < 0.001); attack onset between midnight and 3 am (p = 0.029), and eyelid edema (p = 0.001) were associated with shorter DD. The number of pain episodes before neurology consultation strongly correlated with DD (ρ = 0.92; p < 0.001), underscoring the impact of referral delays. Most patients (59.4%) received alternative diagnoses, mainly migraine and sinusitis. Prior triptan (p = 0.037) and topiramate use (p = 0.012) were linked to longer DD. Multivariate models highlighted age at onset and clinical features as primary predictors, explaining nearly 60% of variance. Diagnostic delay in CH remains considerable in Portugal. Increasing awareness among primary care physicians and non-neurologist specialists is crucial to reduce DD and inappropriate treatments. Further research should clarify the role of educational level and support targeted interventions for timely recognition.
Introduction Migraine is one of the most disabling neurological diseases and is aggravated by anxiety, stress, and sleep dysfunction. Recent studies have shown worsening of migraine associated with the COVID-19 infection and the pandemic more broadly. COVID-19 vaccination has also been associated with symptomatic headache, with high frequency among migraineurs. We aim to assess the impact of COVID-19 diagnosis and vaccine administration on migraine, during the SARS-CoV-2 pandemic. Methods An online questionnaire was sent to migraine patients followed in a neurology outpatient clinic. The survey inquired about migraine symptoms and treatment changes, as well as sleep changes, anxiety and depressive symptoms during the pandemic, after a COVID-19 diagnosis and/or vaccination. Results Out of the 185 patients included, 108 (58.4%) reported a change in headache pattern (42% before a COVID-19 diagnosis) and 72.2% needed to escalate treatment during the pandemic, regardless of infection. Migraine worsening was associated with higher rates of persistent symptomatic headache. A change in sleep pattern was more frequently reported in migraineurs after COVID-19 and in the group with worsening migraine. Abnormal levels of anxiety and depression were high among patients with worsening migraine, irrespective of COVID-19 diagnosis. After vaccination, 49 (27.1%) described a change in headache pattern, with worsening pattern in 29 (16%), 48% up to 3 weeks. Conclusion Worsening of migraine was more likely associated to psychosocial factors related to the pandemic rather than COVID-19 diagnosis per se. COVID-19 vaccination might have acted as an additional but less relevant and temporary trigger for migraine worsening.
9 February 2026 in Current Genetic Medicine Reports
Purpose of Review: >Charcot-Marie-Tooth neuropathy type 4B3 (CMT4B3) is a rare inherited neuropathy caused by SBF1 gene defects, presenting with progressive sensory-motor polyneuropathy, cerebellar ataxia, and cranial nerve involvement. Sjögren syndrome may also cause cranial and peripheral neuropathies. Recent Findings: We report a woman with mild cerebellar ataxia, progressive sensory-motor polyneuropathy worsened after pregnancy, scoliosis, pes cavus , and oculomotor abnormalities. Elevated anti-SSA/Ro and ANA suggested neuro-Sjögren after excluding other causes. Atypical progression and unclear diagnosis prompted whole-exome sequencing-based testing, revealing two novel heterozygous variants in SBF1 gene. A literature review was performed to describe similar cases. Summary: This case highlights the challenge in distinguishing hereditary from acquired neuropathies and emphasizes genetic testing’s role in complex cases, expanding CMT4B3’s clinical spectrum.
16 August 2023 in Movement Disorders Clinical Practice